PMID- 24926422
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140613
LR  - 20211021
IS  - 2193-1801 (Print)
IS  - 2193-1801 (Electronic)
IS  - 2193-1801 (Linking)
VI  - 3
DP  - 2014
TI  - Identification and cost of adverse events in metastatic breast cancer in taxane 
      and capecitabine based regimens.
PG  - 259
LID - 10.1186/2193-1801-3-259 [doi]
LID - 259
AB  - PURPOSE: We sought to compare the economic impact of treatment-related adverse 
      events (AEs) in patients with metastatic breast cancer (mBC) using taxane- or 
      capecitabine-based treatment regimens as either first- or second-line (FL or SL) 
      therapy in the US. METHODS: We used healthcare claims data from the Truven Health 
      Analytics MarketScan(R) Commercial Databases to conduct a retrospective cohort 
      study comparing the economic impact of AEs amongst taxane- and 
      capecitabine-treated mBC patients in the US. We selected women diagnosed with mBC 
      between 2008-2010 who received a taxane or capecitabine as first- or second-line 
      (FL or SL) chemotherapy. Costs related to hospitalization, outpatient services, 
      emergency department visits, chemotherapy and other medications were tabulated 
      and combined to determine total healthcare costs. The incremental monthly costs 
      associated with the presence of AEs compared to no AEs were estimated using 
      generalized linear models, controlling for age and Charlson Comorbidity Index. 
      RESULTS: We identified 15,443 mBC patients meeting inclusion criteria. Adjusted 
      total monthly costs were significantly higher in those who experienced AEs than 
      in those without AEs in both lines of treatment (FL incremental cost: taxanes 
      $1,142, capecitabine $1,817; SL incremental cost: taxanes $1,448, capecitabine 
      $4,437). Total costs increased with the number of AEs and were primarily driven 
      by increased hospitalization amongst those with AEs. CONCLUSIONS: Adverse events 
      in taxane- or capecitabine-treated mBC patients are associated with significant 
      increases in costs. Selecting treatment options associated with fewer AEs may 
      reduce costs and improve outcomes in these patients.
FAU - Hansen, Ryan N
AU  - Hansen RN
AD  - University of Washington, Seattle, WA USA ; Pharmaceutical Outcomes Research and 
      Policy Program, School of Pharmacy, University of Washington, 1959 NE Pacific 
      Ave, H-375Q, Box 357630, Seattle, WA 98195-7630 USA.
FAU - Ramsey, Scott D
AU  - Ramsey SD
AD  - University of Washington, Seattle, WA USA ; Fred Hutchinson Cancer Research 
      Center, Seattle, WA USA.
FAU - Lalla, Deepa
AU  - Lalla D
AD  - Genentech Inc, South San Francisco, CA USA.
FAU - Masaquel, Anthony
AU  - Masaquel A
AD  - Genentech Inc, South San Francisco, CA USA.
FAU - Kamath, Tripthi
AU  - Kamath T
AD  - Genentech Inc, South San Francisco, CA USA.
FAU - Brammer, Melissa
AU  - Brammer M
AD  - Genentech Inc, South San Francisco, CA USA.
FAU - Hurvitz, Sara A
AU  - Hurvitz SA
AD  - UCLA/Jonsson Comprehensive Cancer Center, Los Angeles, CA USA.
FAU - Sullivan, Sean D
AU  - Sullivan SD
AD  - University of Washington, Seattle, WA USA ; Fred Hutchinson Cancer Research 
      Center, Seattle, WA USA.
LA  - eng
PT  - Journal Article
DEP - 20140521
PL  - Switzerland
TA  - Springerplus
JT  - SpringerPlus
JID - 101597967
PMC - PMC4047276
OTO - NOTNLM
OT  - Adverse effects
OT  - Antineoplastic agents
OT  - Breast neoplasms
OT  - Costs and cost analysis
EDAT- 2014/06/14 06:00
MHDA- 2014/06/14 06:01
PMCR- 2014/05/21
CRDT- 2014/06/14 06:00
PHST- 2014/05/14 00:00 [received]
PHST- 2014/05/15 00:00 [accepted]
PHST- 2014/06/14 06:00 [entrez]
PHST- 2014/06/14 06:00 [pubmed]
PHST- 2014/06/14 06:01 [medline]
PHST- 2014/05/21 00:00 [pmc-release]
AID - 982 [pii]
AID - 10.1186/2193-1801-3-259 [doi]
PST - epublish
SO  - Springerplus. 2014 May 21;3:259. doi: 10.1186/2193-1801-3-259. eCollection 2014.